On December 12th at an awards ceremony in Paris, Dr. Michel C. Nussenzweig was presented with the Sanofi-Institut Pasteur Award for his achievements in research on the molecular aspects of adaptive and innate immune responses, and HIV antibodies.
Sanofi, a global diversified healthcare leader, and the Institut Pasteur, an internationally renowned biomedical research center, jointly created in 2012 the Sanofi-Institut Pasteur Awards to recognize scientists for their past or ongoing research demonstrating real scientific progress in the life sciences. This year, the jury composed of ten distinguished members of the research community, recognized the work of five scientists whose outstanding research is contributing to progress in global public health, specifically in the fields of immunology, and microbiology and infection.
Nussenzweig studies molecular aspects of the immune system's adaptive and innate responses, specifically B lymphocytes and antibodies to HIV-1 and dendritic cells. His research has led to the development of innovative new vaccines against pathogens and new treatments for autoimmunity. Much of the work in the Nussenzweig laboratory focuses on isolating and cloning human antibodies for use in clinical studies of HIV-1 prevention and therapy. In pre-clinical and clinical trials, 3BNC117 and 10-1074, broadly neutralizing antibodies isolated from HIV-infected individuals, have been shown to interfere with chronic infection in a way that traditional antiretroviral therapy do not, suggesting it could lead to long-term control of the virus.
For more information, please see the Institut Pasteur website or the